Regulus Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$8.16(as of Jun 24, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Regulus Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$8.16
Ticker SymbolRGLS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees34
CountyUSA
Market Cap$565.0M
EBIDTA-51.4M
10-Day Moving Average8.15
P/E Ratio-11.36
20-Day Moving Average8.08
Forward P/E Ratio0.00
50-Day Moving Average6.65
Earnings per Share-0.68
200-Day Moving Average2.76
Profit Margin-2,833.53%
RSI66.62
Shares Outstanding69.2M
ATR0.17
52-Week High8.35
Volume0
52-Week Low0.83
Most Recent Support Level7.75
Book Value69.0M
Most Recent Resistance Level8.29
P/B Ratio7.82
Upper Keltner8.47
P/S Ratio1,588.19
Lower Keltner7.69
Debt-to-Equity Ratio8.47
Next Earnings Date08/12/2025
Cash Surplus45.1M
Next Ex-Dividend DateUnknown

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.